On Tuesday, Oncolytics Biotech, Inc (NASDAQ: ONCY) was 4.17% up from the session before settling in for the closing price of $0.99. A 52-week range for ONCY has been $0.33 – $1.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 23.13% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 19.59%. With a float of $98.09 million, this company’s outstanding shares have now reached $100.36 million.
Oncolytics Biotech, Inc (ONCY) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Oncolytics Biotech, Inc stocks. The insider ownership of Oncolytics Biotech, Inc is 2.27%, while institutional ownership is 9.64%.
Oncolytics Biotech, Inc (ONCY) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.12 earnings per share (EPS) during the time that was less than consensus figure (set at -0.11) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.32% during the next five years compared to 23.13% growth over the previous five years of trading.
Oncolytics Biotech, Inc (NASDAQ: ONCY) Trading Performance Indicators
You can see what Oncolytics Biotech, Inc (ONCY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Oncolytics Biotech, Inc (ONCY)
Let’s dig in a bit further. During the last 5-days, its volume was 0.52 million. That was inferior than the volume of 0.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.74%.
During the past 100 days, Oncolytics Biotech, Inc’s (ONCY) raw stochastic average was set at 68.76%, which indicates a significant decrease from 77.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0899 in the past 14 days, which was higher than the 0.0757 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9743, while its 200-day Moving Average is $0.7705. However, in the short run, Oncolytics Biotech, Inc’s stock first resistance to watch stands at $1.0633. Second resistance stands at $1.0967. The third major resistance level sits at $1.1533. If the price goes on to break the first support level at $0.9733, it is likely to go to the next support level at $0.9167. Assuming the price breaks the second support level, the third support level stands at $0.8833.
Oncolytics Biotech, Inc (NASDAQ: ONCY) Key Stats
There are 100,361K outstanding shares of the company, which has a market capitalization of 104.28 million. As of now, sales total 0 K while income totals -23,140 K. Its latest quarter income was 0 K while its last quarter net income were -4,460 K.
